Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 8:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 1,450 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Safety in Healthy Adults Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

DMID 23-0015; Lassa Fever CVD 1000

NCT06546709
View directory record Official record
Conditions
Lassa Fever
Interventions
LASSARAB+ aPHAD-SEat 700rU, HDCV Comparator, Normal Saline Placebo, LASSARAB+ aPHAD-SEat 1400rU
Biological · Other
Lead sponsor
Wilbur Chen, MD, MS
Other
Eligibility
18 Years to 50 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 24, 2026, 8:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety Study to Evaluate Pazopanib Eye Drops in Healthy Volunteers

NCT01072214
View directory record Official record
Conditions
Macular Degeneration
Interventions
pazopanib, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
20 Years to 64 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Oct 24, 2026, 8:30 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® Vaccine

NCT02117934
View directory record Official record
Conditions
Healthy
Interventions
HEPLISAV, Engerix-B
Biological
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
18 Years to 70 Years
Enrollment
8,374 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
40
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Oct 24, 2026, 8:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Study of Recombinant Ricin Toxin A-Chain Vaccine (RVEc™)

NCT01317667
View directory record Official record
Conditions
Ricin
Interventions
RVEc
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Fort Deterick, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 3, 2020 · Synced Oct 24, 2026, 8:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Multiple Dose Study to Assess the Safety and Tolerability of BMS-963272 in Obese But Otherwise Healthy Adults

NCT04116632
View directory record Official record
Conditions
Obese But Otherwise Healthy Participants
Interventions
BMS-963272, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated May 15, 2020 · Synced Oct 24, 2026, 8:30 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Norovirus Bivalent Virus-Like Particle Vaccine in Healthy Adults

NCT02142504
View directory record Official record
Conditions
Norovirus Prevention
Interventions
Norovirus Bivalent VLP Vaccine, Placebo (Saline)
Biological · Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 49 Years
Enrollment
454 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
10
States / cities
San Diego, California • San Francisco, California • Coral Gables, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2017 · Synced Oct 24, 2026, 8:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics of Intravenous RPX2003 (Biapenem) in Healthy Adult Subjects

NCT01702649
View directory record Official record
Conditions
Healthy Volunteers, Bacterial Infections
Interventions
RPX2003 (Biapenem), Placebo
Drug
Lead sponsor
Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 3, 2012 · Synced Oct 24, 2026, 8:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating IMA-026 in Healthy Subjects

NCT00517348
View directory record Official record
Conditions
Healthy
Interventions
IMA-026
Biological
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 25, 2009 · Synced Oct 24, 2026, 8:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single-dose Safety Study of APD916 in Healthy Volunteers

NCT01093508
View directory record Official record
Conditions
Narcolepsy With or Without Cataplexy
Interventions
APD916
Drug
Lead sponsor
Arena Pharmaceuticals
Industry
Eligibility
18 Years to 45 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 2, 2010 · Synced Oct 24, 2026, 8:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897 in Healthy Adults

NCT02114268
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
MEDI8897 Intravenous, Placebo, MEDI8897 Intramuscular
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
342 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 28, 2016 · Synced Oct 24, 2026, 8:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to Two Different HIV Vaccines, Each Followed by a Adenoviral Vaccine Boost, in HIV Uninfected Adults

NCT00270218
View directory record Official record
Conditions
HIV Infections
Interventions
VRC-HIVADV014-00-VP, VRC-HIVDNA009-00-VP, FFB, PBS
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
7
States / cities
Birmingham, Alabama • San Francisco, California • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 24, 2026, 8:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Open-Label, Single-Dose Study to Evaluate the Safety and PK of DIC075V in Subjects With Renal Insufficiency and Hepatic Impairment Compared to Healthy Subjects and Evaluate the Safety and Pharmacokinetics of HPβCD When Administered in DIC075V Compared to Sporanox® in Healthy Subjects

NCT00805090
View directory record Official record
Conditions
Renal Insufficiency, Chronic, Hepatic Insufficiency, Healthy
Interventions
Sporanox, Diclofenac Sodium
Drug
Lead sponsor
Javelin Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
3
States / cities
Orlando, Florida • Minneapolis, Minnesota • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 30, 2009 · Synced Oct 24, 2026, 8:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers

NCT04527718
View directory record Official record
Conditions
Healthy
Interventions
Placebo, 611
Drug
Lead sponsor
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 10, 2022 · Synced Oct 24, 2026, 8:30 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Extension Study to Further Evaluate the Safety, Pharmacodynamics and Pharmacokinetics of Ozanimod and Active Metabolites

NCT03665610
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ozanimod
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
212 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Austin, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Oct 24, 2026, 8:30 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Ph1, Randomized, Double-Blind and Controlled, Dose Escalation and Expansion Study to Assess the Safety and Pharmacokinetics of JST-010 in Healthy Adults

NCT06943378
View directory record Official record
Conditions
Pre-exposure Prophylaxis Against Pneumonic Plague in Healthy Adults
Interventions
Monoclonal antibody JST-010, Placebo
Biological · Drug
Lead sponsor
Just-Evotec Biologics
Industry
Eligibility
18 Years to 55 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 24, 2026, 8:30 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study of the Safety of PAZ-417 in Healthy Elderly Adults

NCT00663065
View directory record Official record
Conditions
Healthy
Interventions
PAZ-417
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
65 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 4, 2009 · Synced Oct 24, 2026, 8:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Pharmacokinetics of Genz-682452 in Healthy Men

NCT01674036
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Genz-682452, Placebo
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 19, 2014 · Synced Oct 24, 2026, 8:30 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety of SAB-176 to Prevent the Flu, Given IM in Healthy Adults Compared With Placebo

NCT06435936
View directory record Official record
Conditions
PHA1A
Interventions
Single Ascending Dose of SAB-176, Single Ascending Dose of Placebo
Drug
Lead sponsor
SAb Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 24, 2026, 8:30 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Placebo- Controlled Study to Evaluate the Safety and Immunogenicity of the RSV-F Vaccine in Elderly Adults

NCT02266628
View directory record Official record
Conditions
Respiratory Syncytial Virus (RSV)
Interventions
RSV-F Vaccine, Saline Placebo
Biological
Lead sponsor
Novavax
Industry
Eligibility
60 Years and older
Enrollment
1,599 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
10
States / cities
Redding, California • Stockbridge, Georgia • Lenexa, Kansas + 7 more
Source: ClinicalTrials.gov public record
Updated May 27, 2022 · Synced Oct 24, 2026, 8:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Doses of ABT-494

NCT01741493
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
ABT-494, Placebo, Tofacitinib
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 75 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
5
States / cities
Miami, Florida • Cincinnati, Ohio • Duncansville, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Oct 24, 2026, 8:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Collect Samples for MIST Analysis of Zibotentan and Bioavailability of Zibotentan and Dapagliflozin in Heatlhy Participants

NCT04991571
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Zibotentan (Treatment A), Dapagliflozin (Treatment A), Zibotentan/Dapagliflozin - Formulation 1 (Treatment B), Zibotentan/Dapagliflozin - Formulation 2 (Treatment C)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Oct 24, 2026, 8:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First Time in Human Study in Healthy Male Volunteers for Compound GSK557296.

NCT00549211
View directory record Official record
Conditions
Obstetric Labour, Premature, Premature Ejaculation
Interventions
GSK557296
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 19, 2012 · Synced Oct 24, 2026, 8:30 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Immunogenicity Study of the Eastern Equine Encephalitis (EEE) Vaccine

NCT02654509
View directory record Official record
Conditions
Eastern Equine Encephalitis
Interventions
Eastern Equine Encephalitis Vaccine, Inactivated, Dried, TSI-GSD 104
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 65 Years
Enrollment
138 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2018
U.S. locations
1
States / cities
Fort Deterick, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Oct 24, 2026, 8:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose Study to Assess the Safety, Tolerability and Pharmacokinetics(PK) of PF-06865571

NCT03092232
View directory record Official record
Conditions
Healthy
Interventions
PF-06865571, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 14, 2017 · Synced Oct 24, 2026, 8:30 AM EDT